Skip to Main Content
Our Commitment to Diversity

REPRESENTATIVE EXPERIENCE

Pharma and BioPharma Litigation

Represented a developer of immunology and neurology medications in a patent license and breach of R&D contract action involving client's joint development with a peer of a treatment for ALS.

Represented a pharmaceutical manufacturer in a Hatch-Waxman patent infringement lawsuit filed by a competitor involving our client's afatinib product.

Defended a pharmaceutical manufacturer in a Hatch-Waxman patent infringement lawsuit filed by a competitor involving our client's paclitaxel product. 

Represented a pharmaceutical manufacturer in a Hatch-Waxman patent infringement lawsuit filed by a competitor involving our client's cinacalcet product. Plaintiff dismissed the action pursuant to a settlement.
Represented a generic pharmaceutical company in a trade secret misappropriation lawsuit involving a competitor's use of our client's trade secrets to increase the value of its drug master file for cocaine.
Represented a generic pharmaceutical company in a Lanham Act lawsuit regarding a competitor's alleged false advertising of its C-Topical product (cocaine hydrochloride 4% solution).

Represented multiple specialty pharmaceutical companies as plaintiffs in a Lanham Act false advertising lawsuit involving a competitor's alleged false advertising of its potassium chloride product.

Defended a manufacturer/developer of generic pharmaceuticals in a Hatch-Waxman patent infringement lawsuit filed by a competitor involving our client's posaconazole product.

Defended a manufacturer/developer of generic pharmaceuticals, and a specialty pharmaceutical manufacturer, in a Hatch-Waxman patent infringement lawsuit filed by a competitor involving a generic version of Namzaric.

Defended a manufacturer/developer of generic pharmaceuticals in a patent infringement lawsuit filed by a competitor involving our client's levothyroxine product.

Defended a manufacturer/developer of generic pharmaceuticals in a patent infringement lawsuit filed by a competitor involving our client's launch of a zoledronic acid product. 

Defended a manufacturer/developer of generic pharmaceuticals in a Hatch-Waxman patent infringement lawsuit filed by a competitor involving our client's saxagliptin product.

Represented a manufacturer/developer of generic pharmaceuticals in a Lanham Act lawsuit involving a competitor's alleged false advertising of our client's vasopressin product. 

Defended a specialty biopharmaceutical company in a patent infringement lawsuit filed by a pharmaceutical manufacturer Involving our client's naloxone hydrochloride injection product. After two months, plaintiff voluntarily dismissed the action.
Represented a independent pharmaceutical manufacturer in Germany in asserting its pumpspray trade dress and copyrights against a generic manufacturer.
Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel